Ionis Pharmaceuticals (IONS) has been beaten down lately with too much selling pressure. While the stock has lost 13.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum osc ...

Ionis Pharmaceuticals (IONS) incurred a loss of 95 cents per share for third-quarter 2024, which was narrower than the Zacks Consensus Estimate of a loss of $1.16 per share.Earnings include compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 72 cents compared with a loss of 85 cents per share in the year-ago quarter.Total revenues were $134 million in the third quarter, beating the Zacks Consensus Estimate of $129.0 million. Revenues declined 7% year ov ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading symbol Name of each exchange on which registered Common Stock, $.001 Par Value "IONS" The Nasdaq Stock Market LLC Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Com ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2024 Earnings Conference Call November 6, 2024 11:30 AM ET Company Participants Wade Walke – Senior Vice President of Investor Relations Brett Monia – Chief Executive Officer Eugene Schneider – Chief Clinical Development Officer Kyle Jenne – Chief Global Product Strategy Officer Beth Hougen – Chief Financial Officer Jonathan Birchall – Chief Commercial Officer Eric Swayze – Executive Vice President of Research Richard Geary – Chief Development Officer Conference ...

Q3:24 Business Update and Financial Results November 6, 2024 Nasdaq: IONS On Today's Earnings Call 2 Brett Monia, Ph.D. Chief Executive Officer Eugene Schneider, M.D. Chief Clinical Development Officer Richard Geary, Ph.D. Chief Development Officer Kyle Jenne Chief Global Product Strategy Officer Beth Hougen Chief Financial Officer Eric Swayze, Ph.D. Executive Vice President, Research Jonathan Birchall Chief Commercial Officer Forward-Looking Statements 3 This presentation includes forward-looking statement ...

Exhibit 99.1 1 Ionis reports third quarter 2024 financial results WAINUATM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif., November 6, 2024 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2024. "Today, we stand ...

Ionis Pharmaceuticals (IONS) reported $134 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 6.9%. EPS of -$0.95 for the same period compares to -$1.03 a year ago.The reported revenue represents a surprise of +3.88% over the Zacks Consensus Estimate of $128.99 million. With the consensus EPS estimate being -$1.16, the EPS surprise was +18.10%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compar ...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.10%. A quarter ago, it was expected that this drug discovery and development company would post a loss of $0.95 per share when it actually produced a loss of $0.45, delivering a surprise of 52.63%.Over the last fo ...

WAINUATM U.S. launch progressing well; approved in UK; positive CHMP opinionOlezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in processOn track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif., Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2024."Today, we stand on the cusp of a new era for Ionis, with our first co-comme ...

Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth.I have been considering Ionis (NASDAQ: IONS ) as a potential "strong buy" opportunity for some time. I covered the Carlsbad, California-based developer of antisense, oligonucleotide therapeutics on multiple occasions, most recently in May, short ...